Latest News & Features
Refine Search
Americas
Pfizer is facing three class actions that allege the pharmaceutical company improperly obtained a patent covering its arthritis drug Celebrex (celecoxib) and used it to force generic drug makers into settlements that delay their entry into the market, Law360 has reported. 10 July 2014
article
Johnson & Johnson’s senior vice president of IP, Phil Johnson, may be out of the running for the top job at the US Patent and Trademark Office (USPTO) as the Obama administration reconsiders its choice for the role, insiders have told The Wall Street Journal. 10 July 2014
Americas
French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine). 10 July 2014
article
Tennessee-based law firm Stites & Harbison PLLC has expanded its IP and technology practice with the hire of life sciences partners Kelly Hollowell and Justin McNaughton. 9 July 2014
Americas
US-based Acorda Therapeutics has sued Actavis for infringing four patents covering its multiple sclerosis (MS) drug Ampyra (dalfampridine). 9 July 2014
Asia
Australian biotechnology company NeuClone has signed an agreement with vaccine maker the Serum Institute of India to manufacture and supply ten biosimilar monoclonal antibody drugs around the world. 8 July 2014
Asia-Pacific
Personal health records company MMR Global has entered into a licensing agreement with Australian medical database company Claydata. 7 July 2014
Americas
An ex-employee for a large Chinese seed production company has been arrested in the US for conspiring to steal trade secrets from US agricultural companies including Monsanto. 7 July 2014
Generics
The PharmaSea project is working to make viable drug candidates of novel compounds found under the sea. LSIPR discovers how the EU-funded initiative does it. 7 July 2014
Biotechnology
The EPO generally accepts applications relating to human embryonic stem cells with an effective date after 2008 but discussions about eligibility continue, says Joachim Wachenfeld. 7 July 2014